From Diagnosis to Treatment of Haematological Neoplasms
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067).
Deadline for manuscript submissions: 31 January 2025 | Viewed by 7
Special Issue Editors
Interests: surgical pathology; hematopathology; lymphomas; molecular pathology
Special Issues, Collections and Topics in MDPI journals
Interests: genitourinary pathology; diagnostic biomarkers; prognostic/predictive biomarkers; digital pathology; emolymphopathology; bladder cancer; prostate cancer
Special Issues, Collections and Topics in MDPI journals
Interests: hematopathology; immunohistochemistry; lymphoid neoplasms; myeloid neoplasms
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Several editions of the World Health Organization (WHO) classifications of haematopoietic neoplasms in 2001, 2008 and 2017 served as the international standard for diagnosis.
Since the 4th WHO edition in 2017, significant clinico-pathological, immunophenotypic and molecular advances have been made in the field of hematopoietic neoplasms, contributing to refining diagnostic criteria of several diseases to upgrade entities previously defined as provisional and to identify new entities.
This work resulted in the two recent classifying proposals of hematopoietic neoplasms, the International Consensus Classification (ICC) and the 5th edition of the WHO classification (WHO-HAEM5).
We are pleased to invite you to submit your research papers to this Special Issue, which aims to shape the current landscape of the diagnosis and treatment of haematological neoplasms of both myeloid and lymphoid origin by critically assessing the more recent technological advances in the recognition of novel entities, the detection of prognostic and predictive biomarkers, and the application of precision medicine tools.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) ancillary techniques (including immunohistochemistry, PCR-based methods, and cytogenetics), the identification of prognostic/predictive biomarkers, issues in the diagnosis/differential diagnosis of challenging entities, and the current role of pathology in tailored therapy and precision medicine.
We look forward to receiving your contributions.
Dr. Magda Zanelli
Dr. Francesca Sanguedolce
Dr. Stefano Ascani
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- haematological neoplasms
- biomarkers
- precision medicine
